Kiniksa Pharmaceuticals stock is attractive because it trades near 52-week lows, and its marketed drug gains traction. Click to find out why KNSA is a Hold.

The company reported that its ARCALYST net product revenue amounted to $121.9 million for the fourth quarter and $416.4 million for the full year 2024, representing significant growth ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The ...

In a recent transaction involving Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), Chief Operating Officer Tessari Eben disclosed the sale of 14,000 Class A Ordinary Shares. The shares were ...

The fusion protein Arcalyst (rilonacept), an IL-1 trap that acts as a soluble decoy receptor, is also marketed by Regeneron Pharmaceuticals, of Tarrytown, New York. Ilaris is, however, the first ...

Rystiggo (rozanolixizumab) is a brand-name subcutaneous infusion that’s prescribed for myasthenia gravis. Rystiggo has interactions with some other drugs. Examples include immunoglobulins and ...

Interleukin-1 (IL-1) family cytokines are key signaling molecules in both the innate and adaptive immune systems, mediating inflammation in response to a wide range of stimuli. The basic mechanism of ...

After hours: 7 February at 19:49:44 GMT-5 ...

Pre-Market: 6:59:59 a.m. EST ...